| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30021671 | HIV | ENSG00000105810.10 | protein_coding | CDK6 | Yes | No | 1021 | Q00534 |
| TVIS30067493 | HIV | ENSG00000105810.10 | protein_coding | CDK6 | Yes | No | 1021 | Q00534 |
| TVIS30067494 | HIV | ENSG00000105810.10 | protein_coding | CDK6 | Yes | No | 1021 | Q00534 |
| TVIS30067495 | HIV | ENSG00000105810.10 | protein_coding | CDK6 | Yes | No | 1021 | Q00534 |
| TVIS30067496 | HIV | ENSG00000105810.10 | protein_coding | CDK6 | Yes | No | 1021 | Q00534 |
| TVIS30067497 | HIV | ENSG00000105810.10 | protein_coding | CDK6 | Yes | No | 1021 | Q00534 |
| TVIS30067498 | HIV | ENSG00000105810.10 | protein_coding | CDK6 | Yes | No | 1021 | Q00534 |
| TVIS30067499 | HIV | ENSG00000105810.10 | protein_coding | CDK6 | Yes | No | 1021 | Q00534 |
| TVIS30067500 | HIV | ENSG00000105810.10 | protein_coding | CDK6 | Yes | No | 1021 | Q00534 |
| TVIS30067501 | HIV | ENSG00000105810.10 | protein_coding | CDK6 | Yes | No | 1021 | Q00534 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CDK6 |
|---|---|
| DrugBank ID | DB15442 |
| Drug Name | Trilaciclib |
| Target ID | BE0002212 |
| UniProt ID | Q00534 |
| Regulation Type | inhibitor |
| PubMed IDs | 31504118; 33348420; 33004541; 33595690; 33123968 |
| Citations | Weiss JM, Csoszi T, Maglakelidze M, Hoyer RJ, Beck JT, Domine Gomez M, Lowczak A, Aljumaily R, Rocha Lima CM, Boccia RV, Hanna W, Nikolinakos P, Chiu VK, Owonikoko TK, Schuster SR, Hussein MA, Richards DA, Sawrycki P, Bulat I, Hamm JT, Hart LL, Adler S, Antal JM, Lai AY, Sorrentino JA, Yang Z, Malik RK, Morris SR, Roberts PJ, Dragnev KH: Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol. 2019 Oct 1;30(10):1613-1621. doi: 10.1093/annonc/mdz278.@@Daniel D, Kuchava V, Bondarenko I, Ivashchuk O, Reddy S, Jaal J, Kudaba I, Hart L, Matitashvili A, Pritchett Y, Morris SR, Sorrentino JA, Antal JM, Goldschmidt J: Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial. Int J Cancer. 2020 Dec 21. doi: 10.1002/ijc.33453.@@Lai AY, Sorrentino JA, Dragnev KH, Weiss JM, Owonikoko TK, Rytlewski JA, Hood J, Yang Z, Malik RK, Strum JC, Roberts PJ: CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. J Immunother Cancer. 2020 Oct;8(2). pii: jitc-2020-000847. doi: 10.1136/jitc-2020-000847.@@Li C, Hart L, Owonikoko TK, Aljumaily R, Rocha Lima CM, Conkling PR, Webb RT, Jotte RM, Schuster S, Edenfield WJ, Smith DA, Sale M, Roberts PJ, Malik RK, Sorrentino JA: Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer. Cancer Chemother Pharmacol. 2021 Feb 17. pii: 10.1007/s00280-021-04239-9. doi: 10.1007/s00280-021-04239-9.@@Hart LL, Ferrarotto R, Andric ZG, Beck JT, Subramanian J, Radosavljevic DZ, Zaric B, Hanna WT, Aljumaily R, Owonikoko TK, Verhoeven D, Xiao J, Morris SR, Antal JM, Hussein MA: Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study. Adv Ther. 2021 Jan;38(1):350-365. doi: 10.1007/s12325-020-01538-0. Epub 2020 Oct 29. |
| Groups | Approved; Investigational |
| Direct Classification | |
| SMILES | CN1CCN(CC1)C1=CN=C(NC2=NC3=C(C=C4N3C3(CCCCC3)CNC4=O)C=N2)C=C1 |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL3894860 |
